BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia
Drug Resistance Updates · 2024
DOI: 10.1016/j.drup.2024.101120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Resistance Updates, 2024. Verfasst von Tushuai Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 2…. Hauptthemen laut MEDLINE: Microfilament Proteins, Oncogene Proteins, Leukemia, Myeloid, Acute, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
AIMS: This study aimed to elucidate the biological roles and regulatory mechanisms of B-cell lymphoma 7 protein family member A (BCL7A) in acute myeloid leukemia (AML), particularly its interaction with polypyrimidine tract binding protein 1 (PTBP1) and the effects on cancer progression and drug resistance. METHODS: BCL7A expression levels were analyzed in AML tissues and cell lines, focusing on associations with promoter hypermethylation. Interaction with PTBP1 and effects of differential expression of BCL7A were examined in vitro and in vivo. The impacts on cell proliferation, cycle progression, apoptosis, and differentiation were studied. Additionally, the regulatory roles of BCL7A on interferon regulatory factor 7 (IRF7) and 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) were assessed. RESULTS: BCL7A was downregulated in AML due to promoter hypermethylation and negatively regulated by PTBP1. Upregulation of BCL7A impeded AML cell growth, induced apoptosis, promoted cell differentiation, and decreased cell infiltration into lymph nodes, enhancing survival in mouse models. Overexpression of BCL7A upregulated IRF7 and downregulated HMGCS1, linking to reduced AML cell malignancy and decreased resistance to cytarabine. CONCLUSIONS: BCL7A acts as a tumor suppressor in AML, inhibiting malignant progression and enhancing drug sensitivity through the IRF7/HMGCS1 pathway. These findings suggest potential therapeutic targets for improving AML treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China; School of Biology and Food Engineering, Changshu Inst…
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China; Graduate Department, Shandong First Medical Universit…
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China.
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China; The First Clinical School of Anhui Medical University…
- Key Laboratory of Anti-inflammatory and Immune Medicine, Ministry of Education, Institute of Clinical Pharmacology, Anhui Medical University, Hefei 230032, PR China. Electronic address: yuegu@ahmu.edu.cn.
Zitieren
APA
Li, T., Gao, R., Xu, K., Pan, P., Chen, C., Wang, D., Zhang, K., Qiao, J., & Gu, Y. (2024). BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2024.101120
Vancouver
Li T, Gao R, Xu K, Pan P, Chen C, Wang D, et al. BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia. Drug Resistance Updates. 2024. doi:10.1016/j.drup.2024.101120
BibTeX
@article{Li2024,
author = {Li, Tushuai and Gao, Renjie and Xu, Kaiwen and Pan, Pengpeng and Chen, Congcong and Wang, Daokuan and Zhang, Keyi and Qiao, Jilei and Gu, Yue},
title = {BCL7A inhibits the progression and drug-resistance in acute myeloid leukemia},
journal = {Drug Resistance Updates},
year = {2024},
doi = {10.1016/j.drup.2024.101120}
}
EUVIMED